Literature DB >> 20801952

The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.

Débora R Siqueira1, Mírian Romitti, Andreia P da Rocha, Lucieli Ceolin, Camila Meotti, Aline Estivalet, Marcia K Puñales, Ana Luiza Maia.   

Abstract

The possible role of RET variants in modifying the natural course of medullary thyroid carcinoma (MTC) is still a matter of debate. Here, we investigate whether the RET variants L769L, S836S, and G691S/S904S influence disease presentation in hereditary or sporadic MTC patients. One hundred and two patients with hereditary MTC and 81 patients with sporadic MTC attending our institution were evaluated. The frequencies of RET polymorphisms in hereditary MTC were as follows: L769L, 17.3%; S836S, 7.95%; and S904S/G691S, 18.2%. No associations were observed between these polymorphisms and pheochromocytoma, hyperparathyroidism, lymph node, or distant metastasis. However, patients harboring the S836S variant were younger than those without this allele (17±8.2 vs 28.6±14.4 years, P=0.01), suggesting that these patients had metastases at a young age. Accordingly, the cumulative frequency of local and/or distant metastases as estimated by Kaplan-Meier curves showed that lymph node and distant metastases occurred earlier in patients harboring the S836S variant (P=0.003 and P=0.026 respectively). The S836S allele frequency was higher in sporadic MTC patients than in controls (10.5 vs 3.1%, P=0.01). Individuals harboring the S836S variant were younger (38.6±13.3 vs 48.5±16.7 years, P=0.02) and showed a higher percentage of lymph node and distant metastases (P=0.02 and P=0.04 respectively). Kaplan-Meier estimates of lymph node and distant metastases yielded distinct curves for patients with or without the S836S allele (P=0.002 and P=0.001 respectively). Additional analyses using a COX regression model showed that the S836S variant was independently associated with metastatic disease (hazard ratio 2.82 (95% confidence interval 1.51-5.26), P=0.001). In conclusion, the RET S836S variant is associated with early onset and increased risk for metastatic disease in patients with hereditary or sporadic MTC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20801952     DOI: 10.1677/ERC-09-0312

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  15 in total

Review 1.  Controversies in familial thyroid cancer 2014.

Authors:  Orlo H Clark
Journal:  Ulus Cerrahi Derg       Date:  2014-06-01

2.  Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk.

Authors:  Yuanqi Zhang; Sanming Wang; Xiaodong Chen; Shengchao Huang; Jianwen Li
Journal:  Tumour Biol       Date:  2014-04-04

3.  The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma.

Authors:  Carla Vaz Ferreira Vargas; Lucieli Ceolin; Rafael Selbach Scheffel; Antônio Felippe Benini; Márcia Silveira Graudenz; Ana Luiza Maia
Journal:  Endocrine       Date:  2020-06-13       Impact factor: 3.633

4.  Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma.

Authors:  Vasudha Mishra; Pradnya Kowtal; Pallavi Rane; Rajiv Sarin
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

5.  Genetic diagnosis of a Chinese multiple endocrine neoplasia type 2A family through whole genome sequencing.

Authors:  Zhen-Fang DU; Peng-Fei Li; Jian-Qiang Zhao; Zhi-Lie Cao; Feng Li; Ju-Ming Ma; Xiao-Ping Qi
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

6.  A complex endocrine conundrum.

Authors:  G Bano; V Siedel; N Beharry; P Wilson; T Cranston; S Hodgson
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

Review 7.  Multiple Endocrine Neoplasia: Genetics and Clinical Management.

Authors:  Jeffrey A Norton; Geoffrey Krampitz; Robert T Jensen
Journal:  Surg Oncol Clin N Am       Date:  2015-07-27       Impact factor: 3.495

8.  Advanced medullary thyroid cancer: pathophysiology and management.

Authors:  Carla Vaz Ferreira; Débora Rodrigues Siqueira; Lucieli Ceolin; Ana Luiza Maia
Journal:  Cancer Manag Res       Date:  2013-05-08       Impact factor: 3.989

9.  Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer.

Authors:  H A Deshpande; K Sheth; J A Sosa; S Roman
Journal:  Clin Med Insights Oncol       Date:  2012-10-31

10.  The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association.

Authors:  Laura Fugazzola; Simone De Leo; Michela Perrino
Journal:  Thyroid Res       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.